Medicine & Life Sciences
2-(5,7-diethyl-2-(4-(2-fluoroethoxy)phenyl)pyrazolo(1,5-a)pyrimidin-3-yl)-N,N-diethylacetamide
18%
2-(7-butyl-2-(4-(2-(((18)F)fluoroethoxy)phenyl)-5-methylpyrazolo(1,5-a)pyrimidin-3-yl)-N,N-diethylacetamide
22%
3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
29%
3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol
11%
4-(3-fluoropropyl)glutamic acid
58%
acetamide
13%
alovudine
56%
Apoptosis
10%
Biomarkers
30%
Brain
10%
Brain Mapping
12%
Breast Neoplasms
36%
Cetuximab
15%
Colorectal Neoplasms
28%
cyclen
19%
ErbB Receptors
16%
Estrogen Receptors
19%
Fluorine-18
10%
Fluorodeoxyglucose F18
27%
GABA-A Receptors
19%
Glioma
26%
Glu-NH-CO-NH-Lys-(Ahx)-((68)Ga(HBED-CC))
15%
Glutamine
42%
Growth
11%
Heterografts
37%
In Vitro Techniques
10%
Lab-On-A-Chip Devices
15%
Lanthanoid Series Elements
22%
Ligands
38%
Microfluidics
13%
Microwaves
15%
Molecular Imaging
100%
N,N-diethyl-2-(2-(4-(2-fluoroethoxy)phenyl)-5,7-dimethylpyrazolo(1,5-a)pyrimidin-3-yl)acetamide
28%
N,N-diethylacetamide
10%
N-fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline
15%
Neoplasm Metastasis
11%
Neoplasms
65%
Optical Imaging
27%
Pharmacology
10%
Phosphatidylinositol 3-Kinases
11%
PK 11195
16%
Positron-Emission Tomography
87%
Precision Medicine
17%
Proteins
33%
Radiopharmaceuticals
12%
Structure-Activity Relationship
11%
Synthetic Chemistry Techniques
19%
Therapeutics
18%
Trastuzumab
18%
Triple Negative Breast Neoplasms
10%
Chemistry
1,4,7,10-tetraazacyclododecane
18%
Acid
6%
Benzodiazepine
25%
Benzyloxycarbonyl Group
7%
Biological Marker
15%
Crizotinib
5%
Cyclooxygenase 1 Inhibitor
16%
Drug
5%
Dye
5%
Fluorescence
5%
Fluorescence Microscopy
8%
Fluorination
6%
Folate
5%
Glutamine
14%
Lanthanoid Atom
20%
Macrocycle
8%
Marker
6%
Molecular Probe
10%
Nucleophilicity
5%
Pharmacokinetics
6%
Phosphonic Acid
5%
Positron
28%
Probe
16%
Protein
22%
Purification
5%
Pyrazolopyrimidine
14%
Radiochemical Yield
13%
Radiochemistry
6%
Structure-Activity Relationship
10%
Subcellular Localization
11%
Total Synthesis
5%
Vemurafenib
8%